Check out Jim Cramer's latest trading recommendations on "Action Alerts Plus".
(Updates from 10:45 a.m. ET with closing information.) NEW YORK ( TheStreet) -- Here's what Jim Cramer had to say on CNBC's "Squawk On The Street" Thursday: Cramer noted how strong Biogen Idec ( BIIB) stock is even though the company's ALS drug failed. "I think this is a great company," Cramer said. BIIB shares closed down 1.4% Thursday. Surprised at Stifel Nicolaus upgrading both DR Horton ( DHI) and Toll Brothers ( TOL), Cramer said, "It's a bit late," then added, "This is the impetus behind the group going up." DHI and TOL both closed flat. Cramer thinks the Cisco ( CSCO) upgrade to outperform by RBC is important. "Cisco is doing better than people think," he said. CSCO closed up 1%. Following another upgrade on Priceline.com ( PCLN), Cramer called it "the last darling standing." PCLN was up 1.6%. Speaking about Huntsman ( HUN), Cramer said its new CEO could stabilize and take the stock to $20 a share. HUN ended the day up 3.3%. By contrast, calling it the disaster du jour, Cramer pointed to the stock falloff at Mellanox Technologies ( MLNX) after the CFO left. "Ask Herb Greenberg," he said of his CNBC colleague. "That's all you need to know." MLNX plummeted 17% Thursday. To sign up for Jim Cramer's free Booyah! newsletter, with all of his latest articles and videos, please click here. -- Written by Anthony Buccino in New York.